Answers are grounded in this paper and cite their sources.
BACKGROUND: Identification of germline BRCA1/2 pathogenic variants is crucial for tailoring ovarian cancer treatment and prevention. The purpose of the study was to develop a model to predict BRCA1/2 status in ovarian cancer patients. PATIENTS AND METHODS: The association between clinical-pathological features and BRCA1/2 status was analysed in a series of 1009 ovarian cancer patients, using Fisher's exact test. Logistic regression models and a decision tree classification algorithm were used to develop a risk score. RESULTS: Compared with noncarriers, BRCA1/2 carriers (n = 216; 21.4%) presented more frequently with serous histotype non-low-grade (92.3% versus 71.6%, P < 0.001), family history of ovarian cancer (31.6% versus 5.7%, P < 0.001), family history of breast cancer (53.7% versus 31.6%, P < 0.001), previous breast cancer (20.9% versus 8.5%, P < 0.001), advanced stage (78.8% versus 69.5%, P = 0.019) and younger age (56.9 years versus 60.8 years, P < 0.001). Multivariable logistic regression on 648 patients with complete data confirmed histotype, family history of breast/ovarian cancer, previous breast cancer and age as independently and significantly associated with BRCA1/2 status. After refining the categorization of variables according to decision tree classification algorithm results, odds ratios derived from multivariable logistic regression were used to assign weights from 1 to 3 to each feature (non-low-grade serous histotype = 3, low-grade serous/high-grade endometrioid histotype/family history of ovarian cancer = 2, age at diagnosis <50 years/family and personal history of breast cancer = 1) and to develop a score ranging from 0 to 10, associated with increasing risk of BRCA1/2 variants (from 0.6% for score 0 to 88% for score ≥7). The area under the curve of the score was 0.78 (95% confidence interval 0.74-0.82) and the optimal cut-off was ≥4 points with a sensitivity of 81% and a specificity of 62.3%. CONCLUSIONS: The proposed risk score may improve assessment and counselling of ovarian cancer patients.
No takes yet. Share an insight, caveat, or question.
Innella et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: